

Marguerite Ennis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7705074/publications.pdf>

Version: 2024-02-01

45
papers

5,148
citations

201674

27
h-index

254184

43
g-index

46
all docs

46
docs citations

46
times ranked

5623
citing authors

#	ARTICLE	IF	CITATIONS
1	The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor Positive Breast Cancer. Journal of the National Cancer Institute, 2022, , .	6.3	0
2	Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer. JAMA - Journal of the American Medical Association, 2022, 327, 1963.	7.4	81
3	The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. Journal of the National Cancer Institute, 2021, 113, 192-198.	6.3	24
4	Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. Journal of the National Cancer Institute, 2021, 113, 1465-1475.	6.3	50
5	Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. Npj Breast Cancer, 2021, 7, 74.	5.2	16
6	Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis. Npj Breast Cancer, 2021, 7, 97.	5.2	14
7	Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. JNCI Cancer Spectrum, 2021, 5, pkab066.	2.9	5
8	Prognostic associations of plasma hepcidin in women with early breast cancer. Breast Cancer Research and Treatment, 2020, 184, 927-935.	2.5	5
9	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	2.9	11
10	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	2.9	15
11	A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast, 2019, 48, 17-23.	2.2	73
12	Association of obesity with breast cancer outcome in relation to cancer subtypes.. Journal of Clinical Oncology, 2019, 37, 11557-11557.	1.6	1
13	The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy.. Journal of Clinical Oncology, 2019, 37, 529-529.	1.6	3
14	Sexual health in long-term breast cancer survivors. Breast Cancer Research and Treatment, 2018, 172, 159-166.	2.5	29
15	Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. JNCI Cancer Spectrum, 2018, 2, pky028.	2.9	10
16	CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC).. Journal of Clinical Oncology, 2018, 36, 557-557.	1.6	2
17	Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls. Breast Cancer Research and Treatment, 2017, 164, 451-460.	2.5	15
18	Prophylactic cranial irradiation (PCI). Still a no-brainer?. Lung Cancer, 2015, 89, 4-7.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. <i>Breast Cancer Research</i> , 2015, 17, 32.	5.0	92
20	Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 331-339.	2.5	70
21	Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 485-493.	2.5	13
22	Quality of Life in Long-Term Breast Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2013, 31, 3540-3548.	1.6	102
23	Post-surgical highly sensitive C-reactive protein (hsCRP) and prognosis in early stage in breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 550-550.	1.6	0
24	Insulin- and Obesity-Related Variables in Early-Stage Breast Cancer: Correlations and Time Course of Prognostic Associations. <i>Journal of Clinical Oncology</i> , 2012, 30, 164-171.	1.6	180
25	Breast Cancer Prognosis in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 19-26.	1.6	134
26	Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 821-830.	2.5	213
27	Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 769-781.	2.5	165
28	Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 759-767.	2.5	16
29	Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 647-659.	2.5	37
30	Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2010, 28, 5147-5152.	1.6	106
31	Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3757-3763.	1.6	305
32	High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 517-525.	2.5	77
33	Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, 501-505.	2.4	214
34	Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 39-47.	2.5	92
35	Economic Analysis of Psychosocial Group Therapy in Women with Metastatic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 183-190.	2.5	32
36	Serum Lipids and Outcome of Early-stage Breast Cancer: Results of a Prospective Cohort Study. <i>Breast Cancer Research and Treatment</i> , 2005, 94, 135-144.	2.5	62

#	ARTICLE	IF	CITATIONS
37	Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer?. Journal of Clinical Oncology, 2005, 23, 6037-6042.	1.6	76
38	Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables. Journal of Clinical Oncology, 2004, 22, 4184-4192.	1.6	98
39	Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data. Journal of Clinical Oncology, 2003, 21, 1944-1951.	1.6	124
40	Diet and Breast Cancer: Evidence That Extremes in Diet Are Associated With Poor Survival. Journal of Clinical Oncology, 2003, 21, 2500-2507.	1.6	84
41	Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study. Journal of Clinical Oncology, 2002, 20, 42-51.	1.6	798
42	Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Research and Treatment, 2002, 74, 65-76.	2.5	98
43	The Effect of Group Psychosocial Support on Survival in Metastatic Breast Cancer. New England Journal of Medicine, 2001, 345, 1719-1726.	27.0	819
44	Adjuvant Treatment and Onset of Menopause Predict Weight Gain After Breast Cancer Diagnosis. Journal of Clinical Oncology, 1999, 17, 120-120.	1.6	278
45	Risk of Menopause During the First Year After Breast Cancer Diagnosis. Journal of Clinical Oncology, 1999, 17, 2365-2365.	1.6	503